ArticleTranslational oncology2025

Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response.

Joanna I López-Velazco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.